First German Patients Enroll in Phase 3 Clinical Trials of LMTXTM for Alzheimer's Disease

Clinical trials get under way in Germany with a second-generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer's

BERLIN, 9th January 2014 TauRx Therapeutics Ltd announced today that the first of 50 planned German patients have enrolled in the global Phase 3 clinical trials of LMTX™ for mild to moderate Alzheimer’s disease.

“The initiation of our clinical studies in Germany marks an important step forward in our quest to find a disease-modifying agent that can help slow or halt the progression of Alzheimer’s disease,” said Prof. Claude Wischik, Executive Chairman and Co-Founder of TauRx Therapeutics. “There is currently no available treatment that can slow or halt the progression of Alzheimer’s, so a medicine that can keep people functioning and at home longer is essential.”

The Phase 3 trials of the tau aggregation inhibitor target ‘tau tangles’ in the brain, and could provide the first definitive data on a tau-based treatment that dissolves the tangles and slows or halts Alzheimer’s disease.

Prof. Wischik added, “It is hoped that this study will shed new light on our understanding of how tau tangles form, their role in dementia, and ultimately how to stop them from spreading in the brain. LMTX™ could also provide a basis for preventive treatment of Alzheimer’s before any symptoms appear.”

The two large, Phase 3 studies will involve over 1,500 patients in more than 20 countries, with about 9 medical centres participating in Germany, including the world-renowned Charité Hospital in Berlin.  “It is exciting to see these studies taking place in Germany, with no less than 3 research centres here in Berlin,” said Professor Franz Theuring, of the Charité - Universitätsmedizin Berlin, who heads up the Preclinical Research Unit of TauRx’s  Berlin-based activities. He began his collaboration with Prof. Wischik 16 years ago and his team’s early work with transgenic mouse models has helped build the rationale behind further clinical studies into tau aggregation inhibitors in Alzheimer’s disease.

TauRx’s Phase 3 clinical studies culminate three decades of research by Professor Claude Wischik and colleagues at TauRx Therapeutics, a spin-out company from the University of Aberdeen, Scotland established 11 years ago. According to Deutsche Alzheimer Gesellschaft (the German Alzheimer’s Society), there are currently 1.2 million people in Germany living with dementia. Currently no treatments are available to stop or reverse this devastating disease, with the highest proportion of sufferers in Western Europe.

For more information and updates about the Phase 3 clinical trials in Alzheimer’s disease or TauRx Therapeutics, patients and carers can visit www.alzheimersglobalstudies.net.

 ###

About TauRx Therapeutics

TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company’s tau aggregation inhibitor, LMTX™, is currently in global Phase 3 clinical trials for Alzheimer’s and Frontotemporal Dementia (FTD). LMTX™ targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to tangles. TauRx’s primary research facilities are in Aberdeen, Scotland. For more information, please visit: http://www.taurx.com

 

 Media Contacts:

 (Germany/Europe) Sylvie Berrebi: +44 (0)7795 197271 or sylvie@sciad.com

 (UK/International) Elizabeth Puller: +44 (0)208 834 1447

Email: press@taurx.com